Factor-V-mutation Leiden
(Mutation: G1691A)
Material: | 1 ml EDTA-blood Swab from the mucosa of the inner side of the cheek (oral mucosal cells/dry swab) and consent declaration in accordance with genetic diagnostics law |
Methods: | Amplifikationsverfahren → Real-time-PCR |
Indication | Thrombosis tendency, in case of increased incidence of venous thromboembolism in the family, in case of confirmed APC-resistance, prior to giving oral contraceptives, in case of thromboembolism, in case of habitual miscarriage. |
Please note | Factor-V-mutation Leiden is detected in approximately 20 % – 25 % of patients with initial venous thrombosis and is therefore more common than all other genetic predisposition factors in total. It is passed on in an autosomal dominant way. The molecular-genetic test allows clear differentiation between the heterozygous and homozygous forms of the factor-V-mutation Leiden. In case of a factor-V-mutation of the heterozygous form, the thrombosis risk is about 4 – 8 times higher. When also taking an ovulation inhibitor + smoking, the risk increases x 30 – 80. In total figures this means: Without factor-V-mutation 1 thrombosis per 12.500 women taking ovulation inhibitors per year, with factor-V-mutation 1 thrombosis per 400 women taking ovulation inhibitors per year. The risk of thrombosis can markedly increase with other additional risk factors such as factor-II-mutation, antiphospholipid-antibodies, anti-factor-II- antibodies, immobilization, pregnancy, systemic inflammations. Thrombosis risk is 50 – 100 times higher in patients with factor-V-mutation of the homozygous form and in approximately half of these patients, a thrombosis is to be expected.
Please also refer to section “Thrombosis, tendency for” (Indications directory) |
Accredited | ja |
More Results for the letter F
- Factor II activity (FACT01)
- Prothrombin
- Factor II mutation (FACT02)
- Prothrombin mutation G20210A
- Factor IX activity (FACT11)
- Factor V activity (FACT03)
- Factor V mutation Leiden (FACT04)
- Mutation: G1691A
- Factor VII activity (FACT05)
- Factor VIII activity (FACT06)
- Factor VIII inhibitor (FACT10)
- Factor VIII ristocetin cofactor (von Willebrand factor activity) (FACT08)
- vWF:activity
- Factor VIII von Willebrand factor antigen (FACT07)
- vWF:Ag
- Factor VIII von Willebrand multimers (FACT09)
- Factor X activity (FACT12)
- Factor XI activity (FACT13)
- Factor XII activity (FACT14)
- Hageman-Factor
- Factor XIII activity (FACT15)
- Syn.: fibrin stabilising factor
- Factor–II–activity (FAK2)
- Prothrombin
- Factor-II-mutation (FAK2GM)
- Prothrombin mutation G20210A
- Factor-IX-activity (FAK9)
- Factor-V-activity (FAK5)
- Factor-V-mutation Leiden (FAK5GM)
- Mutation: G1691A
- Factor-VII-activity (FAK7)
- Factor-VIII-activity (FAK8)
- Factor-VIII-inhibitor (FAK8IN)
- Bethesda assay
- Factor-X-activity (FAK10)
- Factor-XI-activity (FAK11)
- Factor-XII-activity (FAK12)
- Hageman factor
- Factor-XIII-activity (FAK13)
- Fibrin-stabilizing factor
- Fasciola hepatica (FASCI, FASCG)
- Common liver fluke
- Fat, total in stool (FETT1)
- Fatty acids, long-chained (LAFS)
- LCFA